Reference health
An Oncolytic Vaccinia Virus Expressing EpCAM Bispecific T-Cell Engager Enhances Immune Response in Solid Tumors
30/30 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
6 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 30 checked references that resolve
resolves10.1158/2326-6066.CIR-19-0628
Intratumoral Delivery of a PD-1–Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade
resolves10.1016/j.ymthe.2018.04.001
Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones
resolves10.1038/nm.3089
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
resolves10.1016/S1470-2045(08)70107-4
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
resolves10.1016/j.omto.2019.03.005
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism
resolves10.1016/j.omto.2020.08.020
Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer
resolves10.1016/j.omto.2020.08.011
High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma
resolves10.1016/j.molimm.2005.07.034
MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
resolves10.1002/ijc.20908
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct
resolves10.1007/s00262-003-0496-2
T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent
resolves10.1038/s41375-018-0014-3
Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation
resolves10.1002/cpt.651
Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
resolves10.1016/j.jhep.2009.10.026
EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma
resolves10.1016/S0140-6736(00)03312-2
Ep-CAM overexpression in breast cancer as a predictor of survival
resolves10.1038/mt.2013.240
T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy
resolves10.1158/0008-5472.CAN-16-1708
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy
resolves10.15252/emmm.201707567
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
resolves10.1097/CJI.0b013e31815ba792
Phase II Trial of B7-1 (CD-86) Transduced, Cultured Autologous Tumor Cell Vaccine Plus Subcutaneous Interleukin-2 for Treatment of Stage IV Renal Cell Carcinoma
resolves10.1158/1078-0432.CCR-08-0276
Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer
resolves10.1007/s00432-010-0905-9
Triple expression of B7-1, B7-2 and 4-1BBL enhanced antitumor immune response against mouse H22 hepatocellular carcinoma
resolves10.1038/nm0697-682
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
resolves10.1016/j.jss.2011.03.067
Combinatorial Therapy for Liver Metastatic Colon Cancer: Dendritic Cell Vaccine and Low-Dose Agonistic Anti-4-1BB Antibody Co-Stimulatory Signal
The 6 references without a DOI — listed, not checked
no DOI — not checkedVaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
no DOI — not checkedBiTE: Teaching antibodies to engage T-cells for cancer therapy
no DOI — not checkedAnti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies
no DOI — not checkedCombination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model
no DOI — not checkedA multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE(R)) antibody construct, in patients with refractory solid tumors
no DOI — not checkedBispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.2139/ssrn.4123194"><img src="https://citestamp.com/citestamped/10.2139/ssrn.4123194/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.2139/ssrn.4123194)